|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-2-20
|
|
pubmed:abstractText |
Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge. Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial. The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/capecitabine,
http://linkedlifedata.com/resource/pubmed/chemical/lapatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BlumJoanne LJL,
pubmed-author:BrufskyAdamA,
pubmed-author:ChristodoulouChristosC,
pubmed-author:CiruelosEvaE,
pubmed-author:DharanBernieB,
pubmed-author:DiérasVéroniqueV,
pubmed-author:GoriStefaniaS,
pubmed-author:GreilRichardR,
pubmed-author:LinNancy UNU,
pubmed-author:LiuMinetta CMC,
pubmed-author:LoiblSibylleS,
pubmed-author:LossignolDominiqueD,
pubmed-author:OlivaCristinaC,
pubmed-author:PaolettiPaoloP,
pubmed-author:PaulDevchandD,
pubmed-author:RochéHenriH,
pubmed-author:RoychowdhuryDebasishD,
pubmed-author:RubinStephen DSD,
pubmed-author:StemmlerHans-JoachimHJ,
pubmed-author:SteplewskiKlaudiaK,
pubmed-author:WardleyAndrewA,
pubmed-author:WinerEric PEP,
pubmed-author:YardleyDeniseD,
pubmed-author:ZembrykiDeniseD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1452-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19228746-Adult,
pubmed-meshheading:19228746-Aged,
pubmed-meshheading:19228746-Aged, 80 and over,
pubmed-meshheading:19228746-Antineoplastic Agents,
pubmed-meshheading:19228746-Brain Neoplasms,
pubmed-meshheading:19228746-Breast Neoplasms,
pubmed-meshheading:19228746-Deoxycytidine,
pubmed-meshheading:19228746-Female,
pubmed-meshheading:19228746-Fluorouracil,
pubmed-meshheading:19228746-Humans,
pubmed-meshheading:19228746-Middle Aged,
pubmed-meshheading:19228746-Prospective Studies,
pubmed-meshheading:19228746-Protein Kinase Inhibitors,
pubmed-meshheading:19228746-Quinazolines,
pubmed-meshheading:19228746-Receptor, erbB-2
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
